Gastroesophageal reflux disease and Barrett's esophagus

Endoscopy

Volumn 36, Issue 2, 2004, Pages 103-109

  Koop, H ^a  

^a Helios Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; BACLOFEN; CISAPRIDE; CYCLOOXYGENASE 2 INHIBITOR; PROTON PUMP INHIBITOR;

ADENOCARCINOMA; ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DYSPLASIA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; LONG TERM CARE; MALIGNANT TRANSFORMATION; META ANALYSIS; METAPLASIA; PATHOPHYSIOLOGY; PRECANCER; PRIORITY JOURNAL; REVIEW; SUTURING METHOD; SYMPTOMATOLOGY;

BARRETT ESOPHAGUS; ELECTROCOAGULATION; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGECTOMY; GASTROESOPHAGEAL REFLUX; HUMANS; POPULATION SURVEILLANCE; PROTON PUMPS; RANDOMIZED CONTROLLED TRIALS; SUTURE TECHNIQUES;

EID: 0842303671     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-814177     Document Type: Review

References (52)

1. Spechler SJ, Jain SK, Tendler DA, Parker RA. Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 1795-1800
2. Shaker R, Castell DO, Senfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98: 1487-1493
3. Mathus-Vieen EMH, Tytgat GNJ. Gastro-oesophageal reflux in obese subjects: Influence of overweight, weight loss and chronic gastric balloon distension. Scand J Gastroenterol 2002; 37: 1246-1252
4. Collings KL, Pierce Pratt F, Rodriguez-Stanley S et al. Esophageal reflux in conditioned runners, cyclists, and weightlifters. Med Sci Sports Exerc 2003; 35: 730-735
5. Cremonini F, Di Caro S, Delgado-Aros S et al. Meta-analysis: The relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 18: 279-289
6. Martinez SD, Malagon IB, Garewal HS et al. Non-erosive reflux disease (NERD): Acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17: 537-545
7. Mäntynen T, Färkkilä M, Kunnamo I et al. The impact of upper GI endoscopy referral volume on the diagnosis of gastroesophageal reflux disease and its complications: 1-year cross sectional study in a referral area with 260,000 inhabitants. Am J Gastroenterol 2002; 97: 2524-2529
8. Pandolfino JE, Richter JE, Ours T et al. Ambulatory esophageal pH monitoring using wireless system. Am J Gastroenterol 2003; 98: 740-749
9. Bowrey DJ, Williams GT, Clark GW. Histological changes in the oesophageal squamous mucosa: Correlation with ambulatory 24 hour pH monitoring. Clin Pathol 2003; 56: 205-208
10. Kawamura M, Ohara S, Koike T et al. The effects of lansoprazole on erosive oesophagitis are influenced by CYP 2C19 polymorphism. Aliment Pharmacol Ther 2003; 17: 965-973
11. Dalby-Payne JR, Morris AM, Craig JC. Meta-analysis of randomized controlled trials on the benefit and risks of using cisapride for the treatment if gastroesophageal reflux in children. Gastroenterol Hepatol 2003; 18: 196-202
12. B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003; 52: 464-470
13. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastroesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003; 17: 243-251
14. Cantu P, Carmagnola S, Savojardo D et al. Effect of non-selective gamma-aminobutyric acid receptor stimulation on motor function of the lower oesophageal sphincter and gastro-oesophageal reflux in healthy human subjects. Aliment Pharmacol Ther 2003; 18: 699-704
15. Koeck GH, Sifrim D, Lerut T et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52: 1397-1402
16. Triadafilopoulos G, DiBase JK, Nostrant TT et al. The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial. Gastrointest Endosc 2002; 55: 149-156
17. Houston H, Khaitan L, Holzman M, Richards WO. First year experience of patients undergoing the Stretta procedure. Surg Endosc 2003; 17: 401-404
18. Corley DA, Katz P, Wo JM et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: A randomized, sham-controlled study. Gastroenterology 2003; 125: 668-676
19. Tam WC, Schoeman MN, Zhang Q et al. Delivery of radiofrequency energy to the lower oesophageal sphincter and gastric cardia inhibits transient lower oesophageal sphincter relaxations and gastro-oesophageal reflux in patients with reflux disease. Gut 2003; 52: 479-485
20. Mahmood Z, McMahon BP, Arfin Q et al. Endocinch therapy for gastroesophageal reflux disease: A one year prospective follow up. Gut 2003; 52: 34-39
21. Velanovich V, Ben-Menachem T, Goel S. Case-control comparison of endoscopic gastroplication with laparoscopic fundoplication in the management of gastroesophageal reflux disease: Early symptomatic outcome. Surg Laparosc Endoscop Percut Tech 2002; 12: 219-223
22. Johnson DA, Ganz R, Aisenberg J et al. Endoscopic, deep mural implantation of Enteryx for treatment of GERD: 6-month follow-up of a multicenter trial. Am J Gastroenterol 2003; 98: 250-258
23. Cohen JA, Arain A, Harris PA et al. Surgical trial investigating nocturnal gastroesophageal reflux and sleep (STRINGERS). Surg Endosc 2003; 17: 394-400
24. Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic fundoplication in a U.S. community. Am J Med 2003; 114: 1-5
25. DiRe CA, Jones MP, Rulyak SJ, Kahrilas PJ. The economics of laparoscopic Nissen fundoplication. Clin Gastroenterol Hepatol 2003; 1: 328-332
26. Hagedorn C, Jonson C, Lonroth H et al. Efficacy of an anterior as compared with a posterior laparoscopic partial fundoplication: Results from a randomized controlled trial. Ann Surg 2003; 238: 189-196
27. Crysos E, Tsiaoussis J, Zoras OJ et al. Laparoscopic surgery for gastroesophageal reflux disease with impaired esophageal peristalsis: Total or partial fundoplication? J Am Coll Surg 2003; 197: 8-15
28. Jaspersen D, Kulig M, Labenz J et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: An analysis based on the ProGERD study. Aliment Pharmacol Ther 2003; 17: 1515-1520
29. Poe RH, Kallay MC. Chronic cough and gastroesophageal reflux disease: Experience with specific therapy for diagnosis and treatment. Chest 2003; 123: 679-684
30. Green BT, Broughton WA, O'Connor JB. Marked improvement in nocturnal gastroesophageal reflux in a large cohort of patients with obstructive sleep apnea treated with continuous positive airway pressure. Arch Intern Med 2003; 163: 41-45
31. Anderson LA, Murray SJ et al. Mortality in Barrett's oesophagus: Results from a population based study. Gut 2003; 52: 1081-1084
32. Taha AS, Angerson WJ, Morran CG. Reflux and Barrett's oesophagus after gastric surgery: Long-term follow-up and implications for the roles of gastric acid and bile in oesophagitis. Aliment Pharmacol Ther 2003; 17: 547-552
33. Kaur BS, Triadafiloloulos G. Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol 2002; 283: G327-334
34. 2 receptor. Gastroenterology 2003; 124: 615-625
35. Doak SH, Jenkins GJS, Parry EM et al. Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut 2003; 52: 623-628
36. Fitzgerald RC, Abdala S, Onwuegbusi BA et al. Inflammatory gradient in Barrett's oesophagus: Implications for disease complications. Gut 2002; 51: 316-322
37. Egger K, Werner M, Meining A et al. Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new imaging techniques. Gut 2003; 52: 18-23
38. Mandal A, Playford RJ, Wicks AC. Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK. Aliment Pharmacol Ther 2003; 17: 1319-1324
39. Inadomi JM, Sampliner R, Lagergren J et al. Screening and surveillance for Barrett esophagus in high-risk groups: A cost-utility analysis. Ann Intern Med 2003; 138: 176-186
40. Kearny DJ, Crump C, Maynard C, Boyko EJ. A case-control study of endoscopy and mortality from adenocarcinoma of the esophagus or gastric cardia in persons with GERD. Gastrointest Endosc 2003; 57: 823-829
41. Breyer HP, De Barros SGS, Maguilnik I, Edelweiss MI. Does methylene blue detect intestinal metaplasia in Barrett's esophagus? Gastrointest Endosc 2003; 57: 505-509
42. Olliver JR, Wild CP, Sahay P et al. Chromoendoscopy with methylene blue and associated DNS damage in Barrett's oesophagus. Lancet 2003; 362: 373-374
43. Basu KK, Pick B, Bale R et al. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: Factors determining persistence and recurrence of Barrett's epithelium. Gut 2002; 51: 776-780
44. Morino M, Rebechi F, Giaccone DC et al. Endoscopic ablation of Barrett's esophagus using argon plasma coagulation (APC) following surgical laparoscopic fundoplication. Surg Endosc 2003; 17: 539-542
45. Gurski RR, Peters JH, Ghagen JA et al. Barrett's esophagus can and does regress after antireflux surgery: A study of prevalence and predictive features. J Am Coll Surg 2003; 196: 706-712
46. Chen LQ, Hu CY, Der Sarkissian S et al. Apoptosis in Barrett's oesophagus following antireflux surgery. Br J Surg 2002; 89: 1444-1449
47. Parilla P, Martinez De Haro LF, Ortiz A et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003; 237: 291-298
48. Corley DA, Kerlekowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56
49. Sonnenberg A, Fennerty MB. Medical decision analysis of chemoprevention against esophageal adenocarcinoma. Gastroenterology 2003; 124: 1758-1768
50. Attwood SAE, Lewis CJ, Caplan S et al. Argon plasma coagulation as therapy for high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol 2003; 1: 258-263
51. May A, Gossner L, Pech O et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: Acute phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002; 14: 1085-1091
52. Pacifica RJ, Wang KK, Wongkeesong LM et al. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol 2003; 1: 252-257